FasL (human) (multimeric) (rec.)

CHF 420.00
In stock
AG-40B-0130-C01010 µgCHF 420.00
AG-40B-0130-30103 x 10 µgCHF 840.00
More Information
Product Details
Synonyms MultimericFasL™; MegaFasL; ACRP30headless:APO-1L; ACRP30headless:CD95L; ACRP30headless:CD178; ACRP30headless:TNFSF6; ACRP30headless:Fas Ligand
Product Type Protein
Source/Host HEK 293 cells
Sequence Human FasL (aa 139-281) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag.
Crossreactivity Human
Specificity Binds to human and mouse Fas.
Biological Activity Induces apoptosis of human Jurkat T cells at a concentration of <0.2ng/ml.
MW ~40kDa (SDS-PAGE)
Purity ≥95% (SDS-PAGE)
Endotoxin Content <0.02EU/μg purified protein (LAL test; Lonza).
Concentration 0.1mg/ml after reconstitution.
Reconstitution Reconstitute with 100μl sterile water.
Formulation Lyophilized. Contains PBS.
Other Product Data UniProt link P48023: FasL (human)

FLAG is a registered trademark of Sigma-Aldrich Co.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
PBS containing at least 0.1% BSA should be used for further dilutions.
Use/Stability Stable for at least 6 months after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

MultimericFasL™ is a high activity construct in which two trimeric FasL are artificially linked via the collagen domain of ACRP30. This construct very effectively mimics the natural membrane-assisted aggregation of FasL in vivo. FasL is a cytokine that binds to TNFRSF6/Fas, a receptor that transduces the apoptotic signal into cells. It is involved in cytotoxic T cell mediated apoptosis and in T cell development.

Product References
  1. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003)
  2. A Fas agonist induces high levels of apoptosis in haematological malignancies: P. Greaney, et al.; Leuk. Res. 30, 415 (2006)
  3. Apograft, a Novel Stem Cell Selection Technology, Prevents Graft vs. Host Disease (GvHD) While Preserving Graft vs Leukemia (GvL) Effects: J. Stein, et al.; Biol. Blood Marrow Transplant. 24, 192 (2018)
  4. ASC- and caspase-8-dependent apoptotic pathway diverges from the NLRC4 inflammasome in macrophages: B.L. Lee, et al.; Sci. Rep. 8, 3788 (2018)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.